SLC5A2 and heart failure: Newer heart failure medications such as sacubitril/valsartan or SGLT2 inhibitors were not available at the time of data collection, but in the light of the results of recent milestone studies which have influenced the current heart failure guidelines, these new drugs should be recommended in patients with ischaemic HFrEF, although there was no analysis of patients with and without pMI would benefit identically [3, 15–18].